GTx Presents Preclinical Studies of GTx-758, a Selective Estrogen Receptor Alpha Agonist for First Line Treatment of Advanced Prostate Cancer, and GTx-230, an Orally Available Tubulin Antagonist for Cancer Refractory to Taxa